Skip to main
PAVM
PAVM logo

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc. presents a compelling investment opportunity, as its current valuation reflects a balance between high risks and substantial upside potential. The company is focusing on early-stage commercialization of its innovative medical technologies, with anticipated significant growth in revenue projected for 2025 and 2026. Furthermore, a net present value (NPV) analysis suggests an upward adjustment in the company's valuation, indicating that it remains an attractive investment in the medical technology sector.

Bears say

PAVmed Inc. reported a pro forma net loss of $0.8 million with an earnings per share (EPS) of $(0.05), indicating a weaker performance than anticipated as it fell below both internal and consensus estimates. The company also experienced a decline in EsoGuard test volumes, processing only 2,756 tests in Q2, a decrease from previous quarters, highlighting potential challenges in demand for its diagnostics products. Additionally, several risks have been identified that could hinder PAVmed's operations, including liquidity concerns, regulatory hurdles, competition, and shifts in healthcare priorities, contributing to the negative outlook on the company’s financial health.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.